190 related articles for article (PubMed ID: 30031468)
1. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
Urol Clin North Am; 2018 Aug; 45(3):489-502. PubMed ID: 30031468
[TBL] [Abstract][Full Text] [Related]
2. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
3. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
4. Best Practices for
Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
[No Abstract] [Full Text] [Related]
5. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
[TBL] [Abstract][Full Text] [Related]
6. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan.
Gill HS; Tade F; Greenwald DT; Yonover PM; Savir-Baruch B
Clin Nucl Med; 2018 Jan; 43(1):23-24. PubMed ID: 29189374
[TBL] [Abstract][Full Text] [Related]
8. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
9. Detection of Additional Primary Neoplasms on
Parihar AS; Schmidt LR; Dehdashti F; Wahl RL
J Nucl Med; 2022 May; 63(5):713-719. PubMed ID: 34413144
[TBL] [Abstract][Full Text] [Related]
10. Extraprostatic Uptake of
Robertson MS; Sakellis CG; Hyun H; Jacene HA
AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
[No Abstract] [Full Text] [Related]
11. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
12. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
Sörensen J; Owenius R; Lax M; Johansson S
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700
[TBL] [Abstract][Full Text] [Related]
13. Update on
Parent EE; Schuster DM
J Nucl Med; 2018 May; 59(5):733-739. PubMed ID: 29523631
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
Schuster DM; Nanni C; Fanti S
J Nucl Med; 2016 Oct; 57(Suppl 3):61S-66S. PubMed ID: 27694174
[TBL] [Abstract][Full Text] [Related]
15.
Seierstad T; Hole KH; Tulipan AJ; Strømme H; Lilleby W; Revheim ME; Hernes E
PET Clin; 2021 Apr; 16(2):167-176. PubMed ID: 33648662
[TBL] [Abstract][Full Text] [Related]
16. Deep learning detection of prostate cancer recurrence with
Lee JJ; Yang H; Franc BL; Iagaru A; Davidzon GA
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):2992-2997. PubMed ID: 32556481
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of fluciclovine (
Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
[TBL] [Abstract][Full Text] [Related]
19. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
